Xinyang

Researchers are evaluating the safety, tolerability, and effectiveness of RC278 in treating patients with locally advanced unresectable or metastatic malignant solid tumors. This Phase I/II clinical trial aims to find the maximum tolerated dose and recommended dose for Phase 2, while also assessing side effects and tumor response. Participants will receive RC278 through intravenous infusion every three weeks. Treatment will continue until unacceptable side effects occur, the disease progresses, or the participant withdraws. The study includes a dose escalation period to determine optimal dosing and an evaluation period to monitor effects at the recommended dose. Throughout the 24-month study, participants will undergo regular monitoring for dose-limiting toxicities, adverse events, and effectiveness of treatment using imaging and clinical assessments following RECIST v1.1 criteria. Safety and response rates will be closely tracked to inform future research and treatment strategies.